Skip to main content

Table 2 Changes of clinical endpoints from baseline to week 24

From: A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

Endpoint Placebo (n = 82) Neflamapimod (n = 78) Difference in change (95% CI) P value
HVLT-R combined Z-score Total and Delayed Recall −0.13 (−0.27, 0.01) −0.17 (−0.38, 0.05) −0.03 (-0.23, 0.16) NS
WMS Immediate & Delayed Recall 16.6 (11.1, 22.1) 16.0 (10.5, 21.5) -0.6 (−6.0, 4.8)) NS
CDR-SB 1.0 (0.5, 1.5) 1.1 (0.6, 1.7) 0.1 (−0.4, 0.6) NS
MMSE −0.5 (−1.3, 0.3) −0.8 (−1.7, 0.1) −0.3 (−1.0, 0.5) NS
  1. Except for MMSE, results shown derived from mixed model for repeated measures (MMRM) analysis of change from baseline to week 24. MMSE results from ANCOVA of change from baseline to week 24. Least square means (95% confidence interval) from models are shown